Cerbios-Pharma SA’s Post

Here is the insight of latest edition “ELECTA” in MG2 family launched during recent ACHEMA show!!! For more information, connect with us!!!

In this Pharma's Almanac roundtable, our CEO, Akihiro Ko, shared his thoughts on the most consequential results in #biopharma in 2023. Read more about updates in #RareDiseases, #mRNA and Elixirgen’s work with #TelomereBiologyDisorders (TBDs) here: https://brnw.ch/21wFKZy

#ICYMI, Veranova's CEO, Mike Riley, spoke to Speak Pharma about our recent news and how we are strategically positioned to support increasingly complex drug development projects. During the interview, Mike discussed our recently announced US$ 30 million investment in expanding our #ADC and #HPAPI capabilities and how we are embracing innovative technologies to improve efficiency and optimize project delivery. Find out more by reading the full interview in PharmaCompass.com: https://lnkd.in/gtyrGrVS

📢 Last Chance to Register! Join us tomorrow for an exclusive webinar with Coriolis Pharma on the analysis of a lyophilization model. We’ll dive into the significance of predictive models and robustness assessment methodologies. If you haven’t registered yet, there’s still time. Register here > https://lnkd.in/eSm7DURu For those who register but can’t attend, we’ll provide an exec summary afterwards so you can catch up on the key content that interests you. Looking forward to seeing you there! #Pharma #Lyophilization #PredictiveModels #RobustnessAssessment #CoriolisPharma

📅 Excited to be heading to PMRC Conference 2024 in New Jersey on February 7-8! 🌐 Find the latest innovation on the topic of pharma messaging optimization at the Newristics booth! Join us for an engaging discussion where we will unveil 11 lessons learned from testing 16,000+ pharma messages in market research. Busting myths about the 'Dos and Don’ts' of pharma messaging, this session promises valuable lessons for commercial teams. #PharmaMarketResearch #BehavioralScience #mrx #marketresearch #pharma #science

Looking to extract the maximum impact and value from your CI workshops? Join Alberto Briones, PhD and Servier’s Priyanka Bagmar for their Track Talk ‘CI in action: Powering up your CI toolkit for an effective Competitive Simulation Workshop’ on the second day of the Pharma CI Conference USA. This is not one to miss! #pharmaciconf #pharmaci #pharmaciconference #competitiveintelligence #biopharma #LifescienceDynamics #PharmaCIUSA2024

There has been a fundamental shift in power towards Integrated Care Boards, with them holding financial responsibility for all hospital activity that isn't funded centrally by NHSE. It's no wonder now that having the 42 disparate ICB's will make the hard - harder. nzyme can help you identify the key stakeholders to ensure a successful launch and implementation. - get in touch - hello@nzyme.group #pharma #PharmaceuticalIndustry #ICS #IntegratedCareSystem #marketaccess

In the realm of drug discovery, time is precious and costs can quickly escalate. Traditional methods often involve years of research, extensive laboratory work, and significant financial investment before a viable drug candidate emerges. However, with MAbSilico's innovative AI-based solutions, this landscape is rapidly changing. 🌐 mabsilico.com #DrugDiscovery #BioTechs #Pharma #Insilico

Unleash the power of virtual screening and transform your drug discovery process with Jubilant Biosys. Get in touch with our experts to find out how we can make a difference in your drug discovery journey. Please write to: bd@jubilantbiosys.com to know more about our virtual screening services. #CRO #CDMO #CRDMO #drugdiscovery #innovation #computationalchemistry #medicinalchemistry

👏 New significant milestone achieved by Bioxodes in their mission to treat secondary injuries following hemorrhagic stroke (ICH). Their candidate product, BIOX-101, has successfully passed an important phase in its clinical trial. The independent Data Monitoring Committee (DMC) confirmed positive safety results, allowing the company to proceed with the next stage of patient recruitment. Marc Dechamps, CEO at Bioxodes, emphasized the importance of this progress, stating, "The results on the first 16 patients will be a crucial inflection point, as they are what pharmaceutical companies and major private investors want to see before moving forward and financing us." This achievement marks a significant step towards providing a much-needed treatment for ICH, a condition with no current approved therapies. 👉 Read the full article: https://lnkd.in/eQpWsD-m 👉 Read the full release: https://lnkd.in/eetWK5WE #biotech #stroketreatment